Compare Enveric Biosciences Inc (ENVB) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs iShares MBS ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while iShares MBS ETF trades at $89.7 (market cap $35.45B). The key difference: iShares MBS ETF is far larger — about 5299× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (41,141 versus 4,982,386). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and iShares MBS ETF for 96 Days on average.
| ENVB | MBB | |
|---|---|---|
Market Cap | $6.69M | $35.45B |
Volume | 41,141 | 4,982,386 |
Sector | Health | Fixed Income |
52-Week High | $10.80 | $96.91 |
52-Week Low | $1.27 | $89.09 |
Typical Hold Time | 14 Days | 96 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
MBB, the iShares MBS ETF, trades at $89.22, down 0.16% on the day, with a bearish technical signal from moving averages and oscillators showing mixed signals. The ETF faces headwinds from rising intermediate-term rates and inflation, as noted in recent analysis, while short interest has surged significantly. Recent corporate actions include scheduled dividend payments, but key financial ratios are not available in the provided data.
The outlook for MBB is cautious due to interest rate sensitivity and convexity risks in the mortgage-backed securities market. Investment opportunities exist for income-focused investors attracted to its dividend yield, but risks include further rate hikes and prepayment volatility. Investors should weigh the ETF's role in a diversified fixed income portfolio against potential duration-related losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
